INDO US BIOTECH LTD
INDOUS · General/Diversified · NSE
₹102
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for INDOUS yet. Reason: Data Limited.
Updated 4h ago
YieldIQ Score
—
Piotroski F-Score
2/9
Economic Moat
Moderate
Confidence
24%
ROE
20.7%
Debt/Equity
0.19
WACC
11.1%
Market Cap
₹205.37 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
19.2%
Return on capital employed
EV / EBITDA
12.4×
Enterprise multiple
Debt / EBITDA
2.0×
Leverage vs earnings
Interest Coverage
12.5×
EBIT covers interest
Current Ratio
5.31×
Short-term liquidity
Asset Turnover
1.13×
Revenue per ₹ of assets
Revenue CAGR (3Y)
21.4%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
INDOUS · last 4 annual periods
ROE
20.7%
ROCE
19.2%
Operating Margin
—
Debt / Equity
0.19×
PE
—
EV / EBITDA
—
Historical Financials
INDOUS · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 yfinance | 2024 yfinance | 2025 yfinance | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹50.1 Cr | ₹61.7 Cr | ₹72.8 Cr | ₹104 Cr | +27.5% |
| EBITDA | ₹6.9 Cr | ₹9.3 Cr | ₹11.0 Cr | ₹19.1 Cr | +40.3% |
| EBIT | ₹6.5 Cr | ₹8.5 Cr | ₹10.2 Cr | ₹18.0 Cr | +40.7% |
| PAT | ₹5.1 Cr | ₹7.2 Cr | ₹8.2 Cr | ₹16.3 Cr | +47.6% |
| EPS (diluted) | ₹4.13 | ₹7.51 | ₹4.11 | ₹8.12 | +25.2% |
| CFO | ₹2.7 Cr | ₹0.5 Cr | ₹2.2 Cr | ₹1.4 Cr | -19.3% |
| CapEx | ₹-4.0 Cr | ₹-1.8 Cr | ₹-2.6 Cr | ₹-0.9 Cr | — |
| FCF | ₹-1.3 Cr | ₹-1.3 Cr | ₹-0.4 Cr | ₹0.6 Cr | — |
| Total Assets | ₹55.6 Cr | ₹69.5 Cr | ₹84.5 Cr | ₹97.8 Cr | +20.7% |
| Total Debt | ₹12.8 Cr | ₹11.6 Cr | ₹14.3 Cr | ₹14.8 Cr | +4.9% |
| Shareholders' Equity | ₹38.5 Cr | ₹54.5 Cr | ₹62.7 Cr | ₹78.5 Cr | +26.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
INDOUS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
SIKKO SIKKO | — | — | Pending | 5.2% | — |
NAGAFERT NAGAFERT | — | — | Pending | — | — |
NOVAAGRI NOVA AGRITECH LIMITED | +7.4% | 28 | Near Fair Value | 12.5% | — |
NATHBIOGEN NATHBIOGEN | — | — | Pending | 6.1% | — |
NARMADA NARMADA | — | — | Pending | 7.3% | — |
Click a ticker to view its fair-value analysis.
Dividend History
1 ex-dividend event on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹0.25/sh
Last payout
2024-12-03
₹0.25
Peak payout
₹0.25
Trailing yield
—
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of INDOUS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for INDOUS →
Compare
Head-to-head with peers
Compare INDOUS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse INDOUSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.